• Journal of Dental Anesthesia and Pain Medicine
• /
• 제20권4호
• /
• pp.195-202
• /
• 2020

Background: Nasotracheal intubation is the most commonly used method to secure the field of view when performing surgery on the oral cavity or neck. Like orotracheal intubation, nasotracheal intubation uses a laryngoscope. Hemodynamic change occurs due to the stimulation of the sympathetic nervous system. Recently, video laryngoscope with a camera attached to the end of the direct laryngoscope blade has been used to minimize this change. In this study, we investigated the optimal effect-site concentration (Ce) of remifentanil for minimizing hemodynamic responses during nasotracheal intubation with a video laryngoscope. Methods: Twenty-one patients, aged between 19 and 60 years old, scheduled for elective surgery were included in this study. Anesthesia was induced by slowly injecting propofol. At the same time, remifentanil infusion was initiated at 3.0 ng/ml via target-controlled infusion (TCI). When remifentanil attained the preset Ce, nasotracheal intubation was performed using a video laryngoscope. The patient's blood pressure and heart rate were checked pre-induction, right before and after intubation, and 1 min after intubation. Hemodynamic stability was defined as an increase in systolic blood pressure and heart rate by 20% before and after nasotracheal intubation. The response of each patient determined the Ce of remifentanil for the next patient at an interval of 0.3 ng/ml. Results: The Ce of remifentanil administered ranged from 2.4 to 3.6 ng/ml for the patients evaluated. The estimated optimal effective effect-site concentrations of remifentanil were 3.22 and 4.25 ng/ml, that were associated with a 50% and 95% probability of maintaining hemodynamic stability, respectively. Conclusion: Nasotracheal intubation using a video laryngoscope can be successfully performed in a hemodynamically stable state by using the optimal remifentanil effect-site concentration (Ce₅₀, 3.22 ng/ml; Ce₉₅, 4.25 ng/ml).

• Journal of Yeungnam Medical Science
• /
• 제21권2호
• /
• pp.198-206
• /
• 2004

gemcitabine과 carboplatin으로 치료받은 경력이 있는 진행성 비소세포폐암 환자 25명을 대상으로 2차 화학요법으로 paclitaxel과 cisplatin을 사용하여 다음과 같은 결과를 확인하였다. 전체 25명 중 5명에서 부분반응이 관찰되었으며, 반응군의 반응지속기간은 2~11개월로 중앙값 4.3개월이었다. 전체 환자의 무진행생존 기간은 0~11개월로 중앙값 3.3개월이었으며, 생존기간은 1.3~39개월로 중앙값 7.4개월이었다. 전체 83회의 화학요법 중 WHO 3도의 혈소판감소증이 1회에서만 관찰되었으며, 비혈액학적 부작용도 감내할만 하였다. 이상의 결과 paclitaxel과 cisplatin 복합화학 요법은 진행서 비소세포폐암 환자에서 2차 요법으로 사용하였을 때 부작용이 적으며 효과적인 치료법의 하나로 판단된다.

• Archives of Plastic Surgery
• /
• 제39권5호
• /
• pp.540-545
• /
• 2012

Background Patients have anxiety and fear of complications due to general anesthesia. Through new instruments and local anesthetic drugs, a variety of anesthetic methods have been introduced. These methods keep hospital costs down and save time for patients. In particular, the target-controlled infusion (TCI) system maintains a relatively accurate level of plasma concentration, so the depth of anesthesia can be adjusted more easily. We conducted this study to examine whether intravenous anesthesia using the TCI system with propofol and remifentanil would be an effective method of anesthesia in breast augmentation. Methods This study recruited 100 patients who underwent breast augmentation surgery from February to August 2011. Intravenous anesthesia was performed with 10 mg/mL propofol and 50 ${\mu}g/mL$ remifentanil simultaneously administered using two separate modules of a continuous computer-assisted TCI system. The average target concentration was set at 2 ${\mu}g/mL$ and 2 ng/mL for propofol and remifentanil, respectively, and titrated against clinical effect and vital signs. Oxygen saturation, electrocardiography, and respiratory status were continuously measured during surgery. Blood pressure was measured at 5-minute intervals. Information collected includes total duration of surgery, dose of drugs administered during surgery, memory about surgery, and side effects. Results Intraoperatively, there was transient hypotension in two cases and hypoxia in three cases. However, there were no serious complications due to anesthesia such as respiratory difficulty, deep vein thrombosis, or malignant hypertension, for which an endotracheal intubation or reversal agent would have been needed. All the patients were discharged on the day of surgery and able to ambulate normally. Conclusions Our results indicate that anesthetic methods, where the TCI of propofol and remifentanil is used, might replace general anesthesia with endotracheal intubation in breast augmentation surgery.

• 대한치과마취과학회지
• /
• 제14권4호
• /
• pp.213-219
• /
• 2014

Background: Clinical use of propofol along with remifentanil for intravenous sedation is increasing in these days, but there are not enough researches to evaluate proper target concentration when these drugs are infused by using target controlled infusion (TCI) pump in dental treatment cases. In this study, we compared efficacy of TCI conscious sedation and target concentration of propofol when it used with or without remifentanil during conscious sedation with the help of a TCI for the surgical extraction of impacted teeth. Methods: After IRB approval, all the charts of patients who had undergone surgical extraction of impacted teeth under propofol TCI sedation for 6 months were selected and reviewed for this study. After reviewal of charts, we could divide patients in two groups. In one group (group 1), only propofol was selected for sedation and initial effect site concentration of propofol was $1{\mu}g/ml$ (n = 33), and in another group (group 2), both propofol and remifentanil was infused and initial effect site concentration of each drug was $0.6{\mu}g/ml$ and 1 ng/ml respectively (n = 25). For each group, average propofol target concentration was measured. In addition, we compared heart rate, respiratory rate, and systolic and diastolic blood pressure as well as oxygen saturation. Besides, BIS, sedation scores (OAAS/S), and subjective satisfaction scores were compared. Results: Between group 1 and 2, there were no significant differences in demographics (age, weight and height), and total sedation time. However, total infused dose and the effect site target concentration of propofol was $163.8{\pm}74.5mg$ and $1.13{\pm}0.21{\mu}g/ml$ in group 1, and $104.3{\pm}46.5mg$ and $0.72{\pm}0.26{\mu}g/ml$ in the group 2 with $1.02{\pm}0.21ng/l$ of the effect site target concentration of remifentanil, respectively. During sedation, there were no differences between overall vital sign, BIS and OAAS/S in 2 groups (P > 0.05). However, we figured out patients in group 2 had decreased pain sensation during sedation. Conclusions: Co-administration of propofol along with remifentanil via a TCI for the surgical extraction of impacted teeth may be safe and effective compared to propofol only administration.

• 대한치과마취과학회지
• /
• 제13권1호
• /
• pp.1-7
• /
• 2013

Background: Intravenous sedation is effective for dental patients who are anxious. Recently, target-controlled infusion (TCI) has begun to be used widely to administer and titrate propofol and remifentanil during sedation. To investigate the effect and safety of the pharmacologic agents used in anesthetic department, we performed a retrospective study. Methods: Retrospective study of a series of dental procedure under intravenous sedation performed in department of anesthesiology in Dental Hospital of Dankook University was carried out with propofol or propofol/remifentanil between January and August 2011 and January and April 2012. All patients received oxygen by nasal cannula. The average propofol and remifentanil target was 0.5 ${\mu}g/ml$ and 1.0 ng/ml, respectively using a TCI pump. The average peripheral oxygen saturation ($SpO_2$), heart rate, blood pressure, respiratory rate, nasal end-tidal $CO_2$ were recorded at 5-10 minute intervals. The age, gender, weight, procedure and sedation time, type of procedure were also recorded. Results: We included 22 cases of 19 adults (group A) and 6 cases of children (group B). In group A, 4 patients received propofol (group A-P), and 15 patients received propofol with remifentanil (group A-PR). In group B, 6 patients received propofol only. The mean age of group A was 41.1 years old and that of group B was 9.5 years old. No clinically significant complications were noted. There were no case of de-saturation <90%. The median respiratory rate was 13.1 (range 6 to 36) in group A and 19 (range 13 to 25) in group B. The median end tidal $CO_2$ was 36.7 mmHg(range 8 mmHg to 56 mmHg) in group A and 41.7 mmHg (range 30 mmHg to 53 mmHg) in group B. Conclusions: Based on our results, dental sedation using propofol/remifentanil in adult and propofol in children with TCI pump seems to appear as a safe and effective procedure while performing dental procedure.

• Journal of Animal Science and Technology
• /
• 제56권2호
• /
• pp.6.1-6.4
• /
• 2014

The aims of study were to investigate the effects of intraperitoneal (i.p.) infusion of ghrelin on pancreatic ${\alpha}$-amylase outputs and the responses of pancreatic proteins to ghrelin that may relate to the pancreatic exocrine. Six male Sprague-Dawley rats (300 g) were randomly divided into two groups, a control group (C, n = 3) and a treatment group (T, $10.0{\mu}g/kg$ BW, n = 3). Blood samples were collected from rat caudal vein once time after one hour injection. The concentrations of plasma ghrelin, cholecystokinin (CCK) and alfa-amylase activity were evaluated by enzyme immunoassay (EIA) kit. Two-dimensional gel electrophoresis (2-DE) analysis was conducted to separate the proteins in pancreas tissue. Results showed that the i.p. infusion of ghrelin at doses of $10.0{\mu}g/kg$ body weight (BW) increased the plasma ghrelin concentrations (p = 0.07) and elevated the plasma CCK level significantly (p < 0.05). Although there was no statistically significant, the ${\alpha}$-amylase activity tended to increase. The proteomics analysis indicated that some pancreatic proteins with various functions were up- or down-regulated compared with control group. In conclusion, ghrelin may have role in the pancreatic exocrine, but the signaling pathway was still not clear. Therefore, much more functional studies focus on these found proteins are needed in the near future.

• The Korean Journal of Pain
• /
• 제20권2호
• /
• pp.169-173
• /
• 2007

Background: Although the use of intravenous patient controlled analgesia (IVPCA) has been compared to the use of patient conrolled epidural analgesia (PCEA), there is no optimal administration route of alfentanil for the treatment of postoperative pain. This randomized double-blind study compared the efficacy of the use of IVPCA and PCEA for postoperative pain and the side effects after a total abdominal hysterectomy (TAH). Methods: Sixty patients undergoing a TAH were randomly assigned to receive either IVPCA (Group I) or PCEA (Group E) for the infusion of alfentanil for postoperative pain control. In both groups, a loading dose of $750{\mu}g$ alfentanil was administered. All patients received the same continuous infusion rate (0.3 mg/h), bolus dose (0.15 mg), and lockout time (15 min). The incidence of side effects, the VAS (visual analog scale) of pain, blood pressure, and heart rate were checked for 20 hours after the loading dose injection. Results: The VAS of pain was not significantly different between the two groups of patients. The onset of the analgesic effect was significantly more rapid in the Group I patients than in the Group E patients. There was no difference in side effects for either group. Conclusions: When considering multiple factors such as the onset of analgesia, technical difficulties or infection after the procedure, IVPCA using alfentanil is more useful than PCEA for postoperative pain control after a TAH.

• Radiation Oncology Journal
• /
• 제13권3호
• /
• pp.233-241
• /
• 1995

Purpose : To analyse clinical outcome and prognostic factors according to treatment modality, this paper report our experience of retrospective study of patients with esophageal cancer Materials and Methods : One hundred and ten patients with primary esophageal cancer who were treated in Presbyterian Medical Center from May 1985 to December 1992. We analysed these patients retrospectively with median follow up time of 28 months, one hundred and four patients($95{\%}$) were followed up from 15 to 69 months. In methods, twenty-eight patients were treated with median radiation dose irradiated 54.3Gy only. Fifty-six patients were treated with combined chemoradiotherapy. Sixteen cases of these patients were treated with concurrent chemoradiation and the other patients(forty cases) were treated sequential chemoradiotherapy. In concurrent chemoradiotherapy group, patients received 5-FU continuous IV infusion for 4 days. Cisplatin IV bolus. and concurrent esophageal irradiation to 30 Gy. After that patients received 5-FU continuous IV, Cisplatin bolus injection and Mitomycin-C bolus IV, Bleomycin continuous IV, and irradiation to 20 Gy. In sequential chemoradiotherapy group, the chemotherapy consisted of 5-FU 1,000mg/$m^2$ administered as a continuous 24 hour intravenous infusion during five days and Cisplatin 80-100mg/$m^2$ bolus injected, or Bleomycin, Vinblastine, Cisplatin, Methotrexate were used of 1 or 2 cycles. After preoperative concurrentm chemoradiation twenty-six patients underwent radical esophagectomy. Results : Ninety-three patients could be examined for response assessment, By treatment modality, response rates were $85.1{\%}$ for radiation alone group and $86.3{\%}$ for combined chemoradiation group. But in operation group, after one cycle of concurrent chemoradiation treatment, response rate was $61.9{\%}$. The pathologic complete response were $15.4{\%}$ in operation group. Overall median survival was II months and actuarial 5-year survival rate was $8{\%}$. The median survival interval was 6 months for radiation alone group, 11 months for combined chemoradiation group and 19 months for operation group. And also median survival was 19 months for complete responder group that 8 months for noncomplete responder group. In univariative analysis, statistically significant prognostic factors were tumor size, clinical stage, tumor response, and operation. In multivariative analysis, significantly better survival was associated with clinical stage, tumor response, radiation dose, and operation. Conclusion : Compared with radiotherapy alone, combined multimodality may improve the median survival in patients with localized carcinoma of the esophagus and toxicity is acceptable.

• 동의생리병리학회지
• /
• 제20권5호
• /
• pp.1261-1270
• /
• 2006

This study was done to investigate the effect of anti-cancer, anti-metastasis and immune response improvement of herbal-acupuncture with Evodiae Fructus herbal infusion solution(EF-HAS). To study the effects of anti-cancer, anti-metastasis and immune response improvement of EF-HAS, we injected EF-HAS into Chung-wan(CV12) of C57BL/6 mice implanted intravenously with Bl6-Fl0 melanoma. Then, we have examined the effect on the increasing of spleen cells, the effect on the number of CD25$^+$/CD4$^+$, CD8$^+$/CD3e$^+$, CD69$^+$/B220$^+$, NK1.1$^+$/CD3e$^+$ cells in mice's PBMCs, the effect on the pulmonary colony number, and the effect on median survival time(MST) and increase of life span(ILS) of C57BL/6 mice implanted intravenously with Bl6-Fl0 melanoma. The following results were obtained; in the experiment groups treated with EF-HAS, the spleen cell proliferation in C57BL/6 mice, the percentage of CD25$^+$/CD4$^+$, CD8$^+$/CD3e$^+$, CD69$^+$/B220$^+$, NK1.1$^+$/CD3e$^+$ cells in C57BL/6 mice's PBMCs, and MST and ILS of C57BL/6 mice implanted intravenously with Bl6-Fl0 melanoma were significantly increased compared with that of the control group. And in the experiment groups treated with EF-HAS, the pulmonary colony number of C57BL/6 mice implanted intravenously with Bl6-Fl0 melanoma was decreased significantly compared with that of the control group. These results support a role for EF-HAS might De usefully applied in treatment of cancer.

• 농업과학연구
• /
• 제2권1호
• /
• pp.199-231
• /
• 1975

우유내(牛乳內)에 잔류(殘留)하는 항생물질(抗生物質)은 starter의 발육(發育)을 억제(抑制)함으로써 산소유제품(酸素乳製品)의 제조(製造)에 막대(莫大) 한 손실(損失)을 가져올 뿐만 아 니라 유우(乳牛)를 음용(飮用)하는데 인류(人類)에 과민병(過敏病)을 비롯한 각종(各種) 질병(疾病)을 일으킬 수 있다는 것은 주지(周知)의 사실(事實)이다. 그러나 기타(其他) 가축(家畜)에 있어서도 모유내(母乳內)에 항생물질(抗生物質)이 출현(出現)할때는 이것을 포유(哺乳)하는 자축(仔畜)에게도 인류(人類)에서와 같은 장애(障碍)를 초래(招來)할 수 있다는 점(点)도 간과(看過)할수 없는 일이다. 이러한 관점(觀點)에서 본연구(本硏究)에서는 유우(乳牛), 산양(山羊) 및 견(犬)에 penicillin, streptomycin 및 oxytetracycline을 근육(筋肉) 또는 정맥내(靜脈內)에 주사(注射)하고 유방내(乳房內)에 주입(注入)할 경우(境遇) 유즙내(乳汁內)에 이해(移行) 또는 잔류(殘留)하는 농도(濃度)와 지속시간(持續時間)을 cylinder-plate법(法)으로 실험(實驗)한바 그 결과(結果)를 요약(要約)하면 다음과 같다. 1) penicillin을 근육주사(筋肉注射)한 후 유즙내(乳汁內)에서 검출(檢出)할 수 있는 penicillin의 최고농도(最高濃度)는 유우(乳牛)가 12시간(時間)에 0.093~0.214(평균(平均) 0.136)I.U./ml, 산양(山羊)이 6시간(時間)에 0.58~0.974(평균(平均) 0.773)I.U./ml, 견(犬)이 3시간(時間)에 0.823~1.482(평균(平均) 1.192)I.U./ml였으며 유즙내(乳汁內) 잔류지속시간(殘留持續時間)은 각각(各各) 60~72시간(時間), 36~48(時間) 및 48~60시간(時間)이었다. 2) streptomycin을 근육주사(筋肉注射)한 후 유즙내(乳汁內)에서 검출(檢出)된 streptomycin 최고농도(最高濃度)는 유우(乳牛)가 6시간(時間)에 0.09~0.47(평균(平均) 0.26)${\mu}g/ml$, 산양(山羊)이 3시간(時間)에 0.17~0.64(평균(平均) 0.45)${\mu}g/ml$, 견(犬)이 3시간(時間)에 0.32~0.96(평균(平均) 0.63)${\mu}g/ml$였으며 유즙내(乳汁內)의 잔류지속시간(殘留持續時間)은 각각(各各) 6~36시간(時間), 12~36(時間) 및 12~24시간(時間)이었다. 3) oxytetracycline을 정맥주사(靜脈注射)한 후 유즙내(乳汁內)에서 검출(檢出)된 oxytetracycline의 최고농도(最高濃度) 유우(乳牛)가 6시간(時間)에 1.5~3.2(평균(平均) 2.4)${\mu}g/ml$, 견(犬)이 6시간(時間)에 1.5~2.4(평균(平均) 2.0)${\mu}g/ml$였으며 잔류지속시간(殘留持續時間)은 유우(乳牛)가 24~48시간(時間), 산양(山羊)및 견(犬)이 36~48시간(時間)이었다. 4) penicillin을 유방내(乳房內) 주입(注入)한 경우 주입방(注入房) 유즙(乳汁)에 잔류(殘溜)하는 시간(時間)은 유우(乳牛)가 48~72시간(時間)이었으며 산양(山羊) 및 견(犬)은 72~84시간(時間)이었다. 5) streptomycin을 유방내(乳房內) 주입(注入)할 경우 주입방(注入房) 유즙내(乳汁內)에 잔류(殘溜)하는 지속시간(持續時間)은 유우(乳牛) 및 산양(山羊)이 48~72시간(時間)이었으며 견(犬)은 48~60시간(時間)이었다. 6) oxytetracycline을 유방내(乳房內) 주입(注入)한 경우 주입방(注入房) 유즙(乳汁)에 잔류(殘溜)하는 시간(時間)은 유우(乳牛)가 48~72시간(時間), 산양(山羊) 36~60시간(時間)이었으며 견(犬)은 48~60시간(時間)이었다. 7) penicillin, streptomycin 및 oxytetracycline을 유방내(乳房內) 주입(注入)한후 주입방내(注入房內) 잔류항생물질(殘留抗生物質)의 농도(濃度)와 지속시간(持續時間)을 검토(檢討)한 결과 유우(乳牛) 및 산양(山羊)에 있어서는 필유량(泌乳量)과의 관계(關係)가 인정(認定)되었고 고생산성(高生産性) 유우(乳牛)나 산양(山羊)에 비(比)하여 저생산성(低生産性) 유유(乳牛)와 산양(山羊)에서 농도(濃度)가 높고 잔류지속시간(殘溜持續時間)도 긴 경향(傾向)을 나타내었다. 8) 유우(乳牛)와 산양(山羊)에 penicillin을 각각(各各) 100,000 I.U., 20,000 I.U., streptomycin은 각각(各各) 500mg, 100mg를, oxytetracycline은 각각(各各) 500mg, 100mg를 유방내(乳房內) 주입(注入)한 결과 비주입방(非注入房) 유즙(乳汁)에서는 항생물질(抗生物質)을 검출(檢出)하지 못하였으나 견(犬)에 있어서는 penicillin 10,000 I.U., streptomycin 20mg, oxytetracycline 25mg를 유방내(乳房內) 주입(注入)할때 비주입방(比注入房) 유즙(乳汁)으로부터 항생물질(抗生物質)을 검출(檢出)할 수 있었다. 검출농도(檢出濃度)는 언제나 혈청내(血淸內)가 유즙내(乳汁內) 보다 더 높았으나 비주입방간(非注入房間)의 차이(差異)는 인정(認定)되지 않았다. 9) 견(犬)에 있어서 비주입방(比注入房)으로의 이행가능(移行可能) 최소(最少) 주입량(注入量)은 penicillin이 2,500 I.U., streptomycin은 5mg, oxytetracycline은 5mg이었다.